Purpose of review Our review focuses on recent developments across many settings regarding the diagnosis, screening and management of delirium, so as to inform these aspects in the context of palliative and supportive care.
INTRODUCTION
Delirium is a complex neurocognitive manifestation of an underlying medical abnormality such as organ failure, infection or drug effects. It occurs frequently in palliative and supportive care, particularly in patients with advanced cancer, wherein most will experience delirium in the terminal phase of the illness [1 & ]. Both advanced age and dementia are recognized risks factors for delirium [2] , and projected demographic changes over the next two decades suggest that both will increase dramatically [3, 4] . Cancer is predominantly a disease of the elderly and an increase in cancer-associated deaths is also expected [5] . The cognitive deficits arising in relation to cancer, its treatment, aging, frailty and their pathophysiological intersection are well highlighted [6, 7] . Given the increasing exposure of practitioners in palliative and supportive care to delirium in the context of a broad spectrum of life-threatening diseases and care settings, their approach to the diagnosis, screening and management of delirium warrants careful consideration. Our review addresses predominantly recent publications and advances in relation to these specific issues. The scope of this review does not include the pivotal role of family support and education to both family and carers in the management strategy.
MEETING THE STANDARD DIAGNOSTIC CRITERIA FOR DELIRIUM
The diagnosis of delirium is based on clinical assessment and is guided by standard criteria [8 & ]:
(1) A disturbance in attention (i.e. reduced ability to direct, focus, sustain, and shift attention) and awareness (reduced orientation to the environment). ( 2) The disturbance develops over a short period of time (usually hours to a few days), represents a change from baseline attention and awareness and tends to fluctuate in severity during the course of a day. (3) An additional disturbance in cognition (e.g. memory deficit, disorientation, language, visuospatial ability or perception). (4) The disturbances in Criteria 1 and 2 are not better explained by another preexisting, established or evolving neurocognitive disorder and do not occur in the context of a severely reduced level of arousal, such as coma. (5) There is evidence from the history, physical examination or laboratory findings that the disturbance is a direct physiological consequence of another medical condition, substance intoxication or withdrawal (i.e. because of a drug of abuse or to a medication), or exposure to a toxin, or is because of multiple etiologies.
Published comparative study data regarding ICD-10 and DSM-5 are limited, given that the latter was only published in mid-2013. However, earlier studies comparing the delirium diagnostic criteria of DSM-IV and ICD-10 suggested that the DSM criteria were more inclusive [12] . In research studies, use of either ICD-10 or DSM-5 criteria is recommended as the gold standard diagnostic criteria [9 & ]. To date, most studies have used earlier DSM versions, as they have been easier to operationalize and standard user-friendly tools have been developed to meet this need, such as the Confusion Assessment Method (CAM) [13] , the most widely used tool to diagnostically screen for delirium in both clinical practice and research studies.
Subsyndromal delirium (SSD) is a more controversial clinical entity than full syndrome delirium [14 & ]. Although SSD does not have universally agreed and clearly defined descriptive diagnostic criteria, it is listed in the neurocognitive disorder section of DSM-5 as 'attenuated delirium syndrome ' [10 & ]. In their systematic review of SSD in older people, Cole et al. [15 & ] defined SSD as the presence of one or more symptoms of delirium, not meeting criteria for delirium and not progressing to delirium. In the 12 studies meeting their inclusion criteria, there was a combined SSD prevalence of 23% (95% confidence interval 9-42%). It is unclear whether SSD should be diagnosed categorically, as defined by Cole et al., or viewed from a broader dimensional perspective and defined on the basis of a subdiagnostic score on a delirium diagnostic tool, such as the Delirium Rating Scale-Revised-98 (DRS-R-98) [16] . In a point prevalence study of delirium in a single acute care hospital, Ryan et al. [17] found an SSD prevalence of 10%, based on a DRS-R-98 subdiagnostic score range of 7-11. Further studies and consensus are needed to better define SSD.
Franco et al. [18] conducted exploratory and confirmatory factor analyses on a pooled 7-country, 14-study dataset of 445 nondemented patients with either full syndrome or subsyndromal delirium, based on DRS-R-98 scores. The study confirmed a core phenotype of delirium, based on three core domains: circadian disturbances (sleep-wake cycle and motor behavior changes); attentional and other cognitive impairments; and higher-level thinking (language, thought processing) deficits. The refinement and development of future versions of standard diagnostic criteria hinges on studies such as this and on more rigorous characterization of the nature of delirium and its core domains. [37] . In terms of delirium recognition and screening, nurses occupy a uniquely strategic position in inpatient care; their 24-h level of patient contact affords an ideal opportunity to observe and record the fluctuating feature of delirium symptoms [33] .
ISSUES REGARDING DELIRIUM RECOGNITION IN CLINICAL PRACTICE

POTENTIAL DELIRIUM SCREENING STRATEGIES AND TOOLS
The ideal screening tool should have a high level of sensitivity, be brief and easy to use with minimal training [9 & ]. In addition to minimizing burden on a vulnerable group of patients, the approach to delirium screening in supportive and palliative care should factor in the contextual aspects such as the specific location or point of care, or status in terms of disease trajectory [9
Cognitive screening tools such as the Short Orientation Memory Concentration Test [38] are likely to be of most use on a more intermittent basis, particularly in relation transitions in the point of care such as emergency department attendance, hospice or acute care admission or outpatient encounters. Meanwhile, purely observational tools such as the Nursing Delirium Screening Scale (Nu-DESC) [39] are better adapted to the continuous surveillance mode of screening that might be required during inpatient care. Some tools have more of a hybrid nature, such as the CAM or the Memorial Delirium Assessment Scale (MDAS) [40] , and include observational and cognitive assessment components. Using item response theory to improve screening brevity, a preliminary study by Yang et al. identified a parsimonious item bank of indicators that align with the major CAM features [41] . Although the MDAS was developed as a severity rating tool, it has also been used but not validated for delirium screening in palliative care [42] .
Recent validation and other delirium screening tool studies are summarized in Table 1 It concluded with the recommendation that the CAM should not replace clinical judgment in the diagnosis of delirium. Although the CAM has been validated in a palliative care population, its sensitivity is very much dependent on user training [54] . Combined use of the bCAM, a brief modified version, along with the Delirium Triage Scale (DTS) in older emergency department patients had an acceptable screening sensitivity range of 78-84% [44] . Interestingly, the DTS, which combines a single test of attention (to spell 'lunch' backwards) and a consciousness score from the Richmond AgitationSedation Scale (RASS) [55] , a brief observational tool, had a very high sensitivity at 98% for both physician and research assistant assessors. In terms of informant input, the Family version of the CAM (FAM-CAM) had a sensitivity of 88% in relation to the CAM as a diagnostic reference [45] , whereas the Single Question in Delirium, the briefest of all tools, had moderately good sensitivity at 80% in a single study [46] . The original Nu-DESC validation study in mixed medical and hemato-oncology patients had a sensitivity of 85.7%, but more recent studies in postsurgical patients [47, 48] , and a study using caregiver ratings in home hospice care [49] ], both observational. Data mainly from hospitalized but also longterm care and emergency department patients suggest that selective or targeted screening based on delirium risk factors or risk score is also an approach worth evaluating [2, 7, [56] [57] [58] , though few data exist in relation to predictive models of delirium in the supportive and palliative care population. Despite demonstrable delirium prevention benefits in many other settings [59] , a single evaluation study in palliative care with substantive methodological limitations showed no benefit [60] . Studies are needed to rigorously evaluate the benefits and potential harms of screening in relation to multiple outcomes such as medical intervention requirements, preventive strategies, delirium reversibility, care needs and economic burden [24 & ].
PHARMACOLOGICAL MANAGEMENT OF DELIRIUM WITH ANTIPSYCHOTICS
There remains a lack of good randomized controlled trial (RCT) evidence for the optimal treatment of delirium in palliative care patients. Furthermore, limited up-to-date clinical practice guidelines on delirium in this patient population are currently available [61 & ]. Consequently, management is largely guided by expert opinion [62 & ]. A survey of international delirium specialists, predominantly geriatricians and internal medicine physicians from Europe, demonstrated an ongoing lack of consensus as to the management of both hyperactive and hypoactive delirium and the frequency of using antipsychotic medications [63 & ]. Haloperidol was the most frequently used antipsychotic for situations in which respondents used pharmacological approaches [63 & ]. A pharmacovigilance study of haloperidol in 119 hospice/palliative care patients with delirium reported an average haloperidol dose of 2.1 mg every 24 h in a mostly elderly population with a poor performance status [64] . Over one-third of patients had a reduction in delirium as measured by the Common Toxicity Criteria for Adverse Events (CTCAE) [65] 
. Both antipsychotics were administered with a flexible oral dose scheduled at bedtime and then every 2-3 h as needed for agitation, up to a set maximum dose per 24 h. Benzodiazepines and other antipsychotic medications were not allowed during the study period and there was no placebo arm. Thirteen out of 24 (54.2%) patients completed 7 days of treatment with quetiapine as compared with 22 of 28 (78.6%) patients who received haloperidol. Results were analyzed on an intention-to-treat basis. Mean doses of antipsychotic used were low: quetiapine 67.6 mg/day and haloperidol 0.8 mg/day. The response rates as measured by the reduction in the DRS-R-98 severity scores were not significantly different between the two groups. The total sleep time per day was greater in the quetiapine group, but was not significantly higher than the haloperidol group.
In a prospective observational study of 2453 general hospital inpatients in Japan, the three most common antipsychotics prescribed by consultationliaison psychiatrists were risperidone (34%), quetiapine (32%) and intravenous haloperidol (20%) for those patients who were unable to take oral antipsychotic [67]. Mean patient age was 73.5 years and the comorbid dementia rate was 30%. Delirium resolved within 1 week in 54% of patients. The rate of serious adverse events was reported as 0.9% with no deaths attributed to antipsychotics. However, electrocardiogram monitoring was not reported. In the study by Hatta et al. . Whereas some published delirium guidelines have suggested doses of antipsychotics, a less prescriptive approach may increase acceptance and uptake of a guideline into clinical practice, with local guideline adaptation specifically tailored for the local culture and environment.
In the elderly, it has been recommended that medications are reserved for severely agitated patients, or those with severe psychotic symptoms, and low antipsychotic starting doses have been suggested for this population, for example haloperidol 0.25-0.5 mg orally twice a day [8 && ].
PHARMACOLOGICAL MANAGEMENT WITH OTHER MEDICATIONS
There is growing evidence to support many hypotheses for the development of delirium, including ]. A case study reported the successful treatment of a delirious 100-year-old Japanese male using a melatonin receptor agonist, ramelteon [76] . An older randomized placebo-controlled double blind trial of 145 internal medicine inpatients (mean age 84.5 years) demonstrated a significant reduction in the risk of delirium [77] ; thus, the role of melatonin in reducing delirium in palliative care patients warrants further study.
Dexmedetomidine, an a 2 -receptor agonist, has been trialed for the treatment and prevention of delirium in ICU patients [78] . For palliative care patients, the roles of dexmedetomidine in the management of delirium sedation at the end of life and analgesia require further evidence [79] .
NON-PHARMACOLOGICAL MANAGEMENT OF DELIRIUM
The role of nonpharmacological strategies in both the prevention and treatment of delirium in many medical ill populations, including elderly and postoperative patients, has been demonstrated [8 && ]. These strategies have been recommended in the recent National Institute for Health and Clinical Excellence clinical practice guidelines, which exclude patients at the end of life [80, 81] . This is in contrast with palliative care populations and older people in long-term institutional care wherein nonpharmacological strategies have yet to demonstrate efficacy in delirium prevention [60, 82] . Deprescribing (the dose reduction, withdrawal, or cessation) of psychoactive medications is an essential step in management in all patient populations [83] , although for patients with advanced cancer, its benefits have not been clearly demonstrated at this time [84] .
As each specialty (e.g. geriatrics, intensive care and palliative care) has a differing patient population, ongoing evidence and consensus should be sought for both the pharmacological and nonpharmacological management of delirium within each patient group. This can then be systematically evaluated for both efficacy, as assessed by delirium severity rating scales that have been validated in that specific population, and adverse effects using standardized tools specific to each particular patient population.
THE ROLE OF HYDRATION IN DELIRIUM MANAGEMENT
A trial of hydration is often given if attempts are made to reverse a delirium episode in line with the patient's goals of care. In a multicenter RCT of 129 hospice patients with cancer, incident delirium levels (as measured by the MDAS) deteriorated in both hydration (1000 ml/day) and placebo patient groups [85] . Similarly, a prospective study of 75 terminally ill cancer patients did not show a difference in the prevalence of hyperactive delirium between hydration and nonhydration groups [86] . Further studies including patients with delirium are needed to provide evidence for this practice.
PALLIATIVE SEDATION
For the optimal symptom management of refractory agitated delirium at the end of life, palliative sedation is frequently necessary, including the home setting [87] [88] [89] [90] . Brinkkemper et al. [91 & ] examined the availability of suitable tools for the appropriate monitoring of palliative sedation by the interprofessional team. A modified Spanish version of the RASS, originally validated in intensive care patients, was developed for the assessment of Spanish patients with advanced cancer [92] . In this study, 38 (24%) of the 156 patients admitted to the palliative care unit were receiving palliative sedation and 57 (37%) had delirium. When used by professionals experienced in palliative care, this modified version of the RASS demonstrated high inter-rater reliability.
In a small mixed-methods pilot study of 10 patients receiving palliative sedation or with an agitated delirium, the RASS-PAL (RASS modified for palliative care inpatients) also showed good psychometric properties and high inter-rater reliability [93] . The inter-rater intraclass correlation coefficient range of the RASS-PAL for the five assessment time points was 0.84-0.98. Training in the appropriate use of these instruments is essential, especially for nonexperienced staff [92, 93] .
CONCLUSION
Delirium continues to be poorly recognized and documented in many care settings, including palliative care. In addition to formal systematic screening, improved interprofessional team communication, educational initiatives and institutional policies that support the implementation of screening and a culture of better delirium recognition are necessary. The quest for briefer yet sensitive delirium screening tools continues and many validation and other tool assessment studies have recently been published. Screening tools should be selected on the basis of contextual need; at some points of care, a cognitive screening tool is most ideal, whereas an observational tool may be more appropriate for continuous inpatient surveillance and screening. Screening in supportive and palliative care settings needs to be critically evaluated in relation to outcomes such as the benefits and burdens of clinical interventions, including preventive measures quality of life and cost. RCTs of pharmacological and nonpharmacological therapeutic strategies are needed to inform the development of guidelines for the management of delirium in palliative and supportive care settings. 
